Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

5.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.5K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

4.6K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
4.6K
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.1K
Production of Formed Elements01:34

Production of Formed Elements

1.6K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
1.6K
Lineage Commitment01:21

Lineage Commitment

3.1K
Commitment is the  process whereby stem cells:
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to: Potential impact of NK-cell education on interferon efficacy in the ENDURE trial.

Leukemia·2026
Same author

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Journal of hematology & oncology·2026
Same author

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.

Cancer genetics·2026
Same author

Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.

Bone marrow transplantation·2026
Same author

Case Report: Pregnant ROS1+ lung cancer patient treated with crizotinib - Impact on infancy.

Frontiers in oncology·2026
Same author

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

The Lancet. Haematology·2026
Same journal

[Progression inhibition in chronic kidney disease].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Optimal blood pressure control in patients with diabetes and arterial hypertension: interpreting the BPROAD study].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Distributive justice in healthcare during times of change: a medical ethics perspective].

Innere Medizin (Heidelberg, Germany)·2026
See all related articles

Related Experiment Video

Updated: Sep 1, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.8K

[Clonal hematopoiesis: causes and clinical implications].

Andreas Burchert1

  • 1Universitätsklinikum Gießen und Marburg, Campus Marburg, Klinik für Hämatologie, Onkologie und Immunologie, Carreras Leukemia Center, Philipps-Universität Marburg, Baldingerstr., 35043, Marburg, Deutschland. burchert@staff.uni-marburg.de.

Innere Medizin (Heidelberg, Germany)
|August 15, 2022
PubMed
Summary
This summary is machine-generated.

Clonal hematopoiesis of indeterminate potential (CHIP) involves stem cell mutations, increasing risks for cardiovascular disease and mortality. Early detection and treatment of CHIP may prevent hematologic cancers and age-related conditions.

Keywords:
Cardiovascular comorbidityClonal hematopoiesis of indeterminate potentialHematologic neoplasmsInflammagingVariant allele frequency

More Related Videos

Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.5K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.4K

Related Experiment Videos

Last Updated: Sep 1, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.8K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.5K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.4K

Area of Science:

  • Hematology
  • Genetics
  • Immunology

Background:

  • Clonal hematopoiesis of indeterminate potential (CHIP) originates from stem cells with mutations in leukemia-associated genes.
  • CHIP confers enhanced stem cell stress tolerance and expansion potential, despite patients appearing hematologically healthy.
  • Aging and chronic inflammation (inflammaging) are primary risk factors for CHIP development.

Purpose of the Study:

  • To investigate the link between CHIP and age-associated comorbidities.
  • To explore the pathomechanisms underlying CHIP.
  • To evaluate the potential of CHIP treatment in preventing hematologic neoplasms and age-related diseases.

Main Methods:

  • Analysis of stem cell mutations in leukemia-associated driver genes.
  • Assessment of CHIP prevalence in relation to age and chronic inflammatory markers.
  • Evaluation of cytokine secretion profiles in CHIP patients.
  • Correlation analysis between CHIP and the incidence of cardiovascular disease, all-cause mortality, and hematologic neoplasms.

Main Results:

  • CHIP is associated with a significantly increased risk of cardiovascular disease and all-cause mortality.
  • CHIP pathogenesis involves increased secretion of proinflammatory cytokines.
  • CHIP is linked to a substantially higher risk of developing hematologic neoplasms.

Conclusions:

  • The correlation between age-associated comorbidities and CHIP detection is significant.
  • Targeting CHIP could potentially mitigate the development of hematologic neoplasms.
  • Intervention in CHIP may offer a strategy to prevent age-associated diseases.